Trials / Completed
CompletedNCT05524545
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
A Phase 1, Open-label, Multicenter, Safety, Pharmacokinetic, Pharmacodynamic Study of ALX148 in Combination With Enfortumab Vedotin and/or Other Anticancer Therapies in Subjects With Urothelial Carcinoma (ASPEN-07)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- ALX Oncology Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
AT148007 is a Phase 1, open-label, multicenter, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Evorpacept | Fusion protein that blocks CD47-SIRPalpha pathway |
| DRUG | Enfortumab Vedotin | Nectin-4 directed antibody and microtubule inhibitor conjugate |
Timeline
- Start date
- 2022-11-02
- Primary completion
- 2025-06-27
- Completion
- 2025-06-27
- First posted
- 2022-09-01
- Last updated
- 2025-07-25
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05524545. Inclusion in this directory is not an endorsement.